JBT Marel Q2 Revenue Misses Slightly, But Adjusted EPS Beats; $33M Impairment and Material Weaknesses Linger
JBTM is trading near its 52-week low of $113.67 (7.3% above the low) on elevated volume (2.9× avg).
Summary
JBT Marel reported Q2 adjusted EPS of $1.95, beating estimates, but took a $33M intangible impairment and disclosed ongoing material weaknesses in internal controls.
Key Events · Earnings and Guidance · JBTM
-
Q2 Earnings Beat on Adjusted Basis
Revenue of $981M missed consensus by a hair, but adjusted EPS of $1.95 exceeded expectations. Adjusted EBITDA rose 7.7% YoY to $168M, driven by higher volume and tariff recoveries.
-
$33M Intangible Asset Impairment
A non-cash impairment charge of $33M was recorded in the Protein Solutions segment, fully writing down certain acquired customer relationship and technology intangibles due to updated business forecasts.
-
Material Weaknesses Remain Unremediated
Material weaknesses in IT general controls and journal entry processing inherited from the Marel acquisition persist, causing management to conclude disclosure controls were not effective as of June 30, 2026.
-
Debt Repayment and Share Buybacks
The company repaid $403M of 2026 convertible notes at maturity and repurchased $26M of common stock under a new $200M share repurchase program authorized in May 2026.
Analysis · JBTM · Technology
JBT Marel's Q2 revenue of $981M came in just below consensus, but adjusted EPS of $1.95 beat estimates. The quarter was marred by a $33M non-cash intangible asset impairment in the Protein Solutions segment, reflecting updated business forecasts. More concerning, the company disclosed that material weaknesses in internal control over financial reporting inherited from the Marel acquisition remain unremediated — a governance red flag that keeps disclosure controls ineffective. On the capital front, the company repaid $403M in convertible notes at maturity and began buying back stock under a new $200M program, signaling confidence in liquidity. The combination of an earnings beat, a large impairment, and persistent control weaknesses makes this a mixed but highly important update.
At the time of this filing, JBTM was trading at $122.01 on NYSE in the Technology sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $113.67 to $170.19. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.